COMMUNIQUÉS West-GlobeNewswire

Lexington Provides Q3 Corporate Review
24/10/2018
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review [...]
Psychemedics Announces Quarterly Results
23/10/2018
Declares 89 th Consecutive Quarterly Dividend ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018 [...]
BioCryst to Report Third Quarter 2018 Financial Results on November 6
23/10/2018
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial results on Tuesday, November 6, [...]
Cutera, Inc. to Announce Third Quarter 2018 Results
23/10/2018
BRISBANE, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, will announce [...]
SeaSpine to Report Third Quarter 2018 Financial Results on November 6, 2018
23/10/2018
CARLSBAD, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
Sientra® to Release Third Quarter 2018 Financial Results on November 6, 2018
23/10/2018
SANTA BARBARA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its third quarter 2018 [...]
LogicBio Therapeutics Announces Closing of Initial Public Offering
23/10/2018
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet [...]
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
23/10/2018
Updated Regulatory Strategy Based on 12-Week Flare-up Data from Completed Phase 2 Program and Consultation with the FDA NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) -- [...]
Clementia annonce son plan de soumettre une présentation de nouvelle drogue (New Drug Application) pour le palovarotène dans le traitement de la FOP à la suite de résultats positifs de la phase 2
23/10/2018
Mise à jour de la stratégie réglementaire en utilisant les données de poussées actualisées de la semaine 12 du programme de phase 2 et en consultation avec la FDA Soumission d’une NDA prévue pour le second semestre de [...]
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
23/10/2018
Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity [...]
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
23/10/2018
PITTSBURGH, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from [...]
HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
23/10/2018
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors TUCSON, Ariz., Oct. 23, 2018 (GLOBE NEWSWIRE) -- [...]
iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results
23/10/2018
Multi-center research presented at ASTRO 2018 shows IORT with the Xoft System is safe with low recurrence and low morbidity in the treatment of breast cancer Company marks 20 years of innovations in targeted cancer care [...]
OV - OV increases its share capital due to warrant exercise
23/10/2018
Hoersholm, Denmark, October 23, 2018 - Oncology Venture today announces that, as a consequence of an exercise of 40,000 warrants by current employee, the share capital in the company will increase by nominal DKK 2,000 [...]
Expert coalition provides recommendations to reduce adverse drug events from anticoagulants during care transitions
23/10/2018
Article appears in November 2018 issue of The Joint Commission Journal on Quality and Patient Safety OAKBROOK TERRACE, Ill. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Anticoagulants, medications that keep the blood from [...]
Fagron NV: Disclosure of received notification
23/10/2018
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 October 2018 - 6:00pm (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron [...]
EUROBIO SCIENTIFIC CERTIFIED ISO 13485 V2016
23/10/2018
EUROBIO SCIENTIFIC CERTIFIED ISO 13485 V2016 Eurobio Scientific has successfully upgraded its quality management systems in order to continue justifying CE marking of its products beyond 2019 Paris, October 23, 2018 - 5 [...]
EUROBIO SCIENTIFIC CERTIFIE ISO 13485 V2016
23/10/2018
EUROBIO SCIENTIFIC CERTIFIE ISO 13485 V2016 Eurobio Scientific a fait évoluer avec succès ses systèmes de management de la qualité pour continuer à justifier du marquage CE de ses produits au-delà de 2019 Paris, le 23 [...]
Transactions in relation to share buyback program
23/10/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Pages